Recently, both preclinical studies and clinical observations have shown that the GLP-1 receptor agonist is effective at increasing GLP-1 activity and at protecting the heart against hypertension, hypertrophy and fibrosis, which is beyond the benefits achieved as an anti-diabetic agent [17,18]. This evidence concerns the gene GLP1R and hypertensive disorder.